文献速递脑血管病

CHA2DS2-VASc评分识别真正低危房颤患者:韩国全国队列研究

CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study.
PubMed 文献 · Stroke · 2017-09-22

该研究基于韩国全国医保样本队列,纳入5855例口服抗凝药初治的非瓣膜性房颤患者,随访至2013年。结果显示CHA2DS2-VASc评分在定义真正低危缺血性卒中患者方面表现良好,其敏感性(98.8%)和阴性预测值(98.8%)均优于CHADS2和ATRIA评分。

要点

  • CHA2DS2-VASc评分低危组缺血性卒中发生率为0.26/100人年。
  • CHA2DS2-VASc对卒中预测的敏感性为98.8%,阴性预测值为98.8%。
  • CHA2DS2-VASc预测5年内无缺血性卒中的比值比为16.4(95%CI 8.8-30.8)。

核心结论

  • CHA2DS2-VASc评分在定义亚洲房颤患者真正低危卒中风险方面表现良好,优于CHADS2和ATRIA评分。

主要发现

  • 基线时CHADS2、CHA2DS2-VASc和ATRIA评分低危组比例分别为17.9%(1049例)、14.7%(860例)和56.0%(3280例)。
  • 随访期间维持低危分类的患者分别为CHADS2 13.9%(811例)、CHA2DS2-VASc 11.4%(667例)和ATRIA 46.6%(2729例)。
  • 低危组缺血性卒中发生率(每100人年)分别为CHADS2 0.42、CHA2DS2-VASc 0.26和ATRIA 1.43。
  • CHA2DS2-VASc预测卒中发生的敏感性为98.8%,优于CHADS2的85.7%和ATRIA的74.8%;阴性预测值为98.8%,优于CHADS2的95.3%和ATRIA的93.7%。
  • CHA2DS2-VASc预测5年随访期间无缺血性卒中的比值比为16.4(95%CI 8.8-30.8)。

临床怎么用

  • 在口服抗凝药初治的非瓣膜性房颤患者中,可使用CHA2DS2-VASc评分识别真正低危、可能不需抗栓治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: As the threshold of stroke risk for initiating oral anticoagulants is lowered after the introduction of the nonvitamin K antagonist oral anticoagulants, the focus of stroke prevention in patients with nonvalvular atrial fibrillation has shifted away from predicting high-risk patients toward initially identifying patients with a truly low risk of ischemic stroke, who do not need antithrombotic therapy. We tested the predictive ability of the congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack (doubled; CHADS2), congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA2DS2-VASc), and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk stratification schemes in oral anticoagulants naive patients with atrial fibrillation in a Korean nationwide sample cohort. METHODS: From January 2002 to December 2008, a total of 5855 oral anticoagulant naive patients with nonvalvular atrial fibrillation aged ≥20 years were enrolled from Korea National Health Insurance Service-Sample Cohort database and were followed-up until December 2013. RESULTS: At baseline, the proportions categorized as low risk using CHADS2, CHA2DS2-VASc, and ATRIA risk stratification schemes were 1049 (17.9%), 860 (14.7%), and 3280 (56.0%), respectively. During follow-up, the low-risk category using CHADS2, CHA2DS2-VASc, and ATRIA scores was retained in 811 (13.9%), 667 (11.4%), and 2729 (46.6%) patients, respectively. Rates of ischemic stroke (100 person-years) in the low risk categories of CHADS2, CHA2DS2-VASc, and ATRIA scores were 0.42, 0.26, and 1.43, respectively. CHA2DS2-VASc had the best sensitivity (98.8% versus 85.7% in CHADS2 and 74.8% in ATRIA) and negative predictive value (98.8% versus 95.3% for CHADS2 and 93.7% for ATRIA) for the prediction of stroke incidence and was best for the prediction of the absence of ischemic stroke during 5 years of follow-up (odds ratio, 16.4 [95% confidence interval, 8.8-30.8]). CONCLUSIONS: The CHA2DS2-VASc score shows good performance in defining truly low-risk Asian patients with atrial fibrillation for stroke compared with CHADS2 and ATRIA scores.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kim TH, Yang PS, Kim D, et al. CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study. Stroke. 2017. PMID: 28939672. doi:10.1161/STROKEAHA.117.018551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。